Bezdjian Aren, Bruijnzeel Hanneke, Daniel Sam J, Grolman Wilko, Thomeer Hans G X M
Department of Experimental Surgery, McGill University, Montreal, Quebec, Canada; McGill Auditory Sciences Lab, McGill University Health Centre Research Institute, Montreal, Quebec, Canada; Department of Otorhinolaryngology - Head and Neck Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands.
Department of Otorhinolaryngology - Head and Neck Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands; Brain Centre Rudolf Magnus, Utrecht, The Netherlands.
Int J Pediatr Otorhinolaryngol. 2017 Oct;101:196-203. doi: 10.1016/j.ijporl.2017.08.014. Epub 2017 Aug 15.
To delineate the auditory functional improvement and peri-operative outcomes of the Sophono™ transcutaneous bone conduction device.
Eligible articles presenting patients implanted with the Sophono™ were identified through a comprehensive search of PubMed and Embase electronic databases. All relevant articles were reviewed to justify inclusion independently by 2 authors. Studies that successfully passed critical appraisal for directness of evidence and risk of bias were included.
From a total of 125 articles, 8 studies encompassing 86 patients using 99 implants were selected. Most patients (79.1%) were children. Ear atresia (67.5%) was the most frequently reported indication for Sophono™ implantation. Overall pure tone average auditory improvement was 31.10 (±8.29) decibel. During a mean follow-up time of 12.48 months, 25 patients (29%) presented with post-operative complications from which 3 were deemed as serious implant-related adverse events (3.5%).
The Sophono™ transcutaneous bone conduction device shows promising functional improvement, no intra-operative complications and minor post-operative skin related complications. If suitable, the device could be a proposed solution for the rehabilitation of hearing in children meeting eligibility criteria. A wearing schedule must be implemented in order to reduce magnet-related skin complications.
描述索诺诺(Sophono™)经皮骨传导装置的听觉功能改善情况及围手术期结果。
通过全面检索PubMed和Embase电子数据库,识别出报道植入索诺诺(Sophono™)装置患者的符合条件的文章。由两名作者独立审查所有相关文章以确定是否纳入。纳入通过证据直接性和偏倚风险关键评估的研究。
从总共125篇文章中,选择了8项研究,涉及86例患者,共植入99个装置。大多数患者(79.1%)为儿童。耳道闭锁(67.5%)是索诺诺(Sophono™)植入最常报道的适应证。总体纯音平均听觉改善为31.10(±8.29)分贝。在平均12.48个月的随访期内,25例患者(29%)出现术后并发症,其中3例被视为严重的与植入装置相关的不良事件(3.5%)。
索诺诺(Sophono™)经皮骨传导装置显示出有前景的功能改善,无术中并发症,术后皮肤相关并发症较少。如果合适,该装置可为符合条件的儿童听力康复提供一种解决方案。必须实施佩戴计划以减少与磁铁相关的皮肤并发症。